A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Malignancies
Interventions: BIOLOGICAL: CDX-1401 in combination with Resiquimod and/or Poly-ICLC|BIOLOGICAL: CDX-1401|BIOLOGICAL: Resiquimod|BIOLOGICAL: poly-ICLC
Sponsor: Celldex Therapeutics